UA98605C2 - Novel method for preventing or treating m. tuberculosis infection - Google Patents

Novel method for preventing or treating m. tuberculosis infection

Info

Publication number
UA98605C2
UA98605C2 UAA200711587A UAA200711587A UA98605C2 UA 98605 C2 UA98605 C2 UA 98605C2 UA A200711587 A UAA200711587 A UA A200711587A UA A200711587 A UAA200711587 A UA A200711587A UA 98605 C2 UA98605 C2 UA 98605C2
Authority
UA
Ukraine
Prior art keywords
tuberculosis infection
fusion protein
preventing
treating
mtb72f
Prior art date
Application number
UAA200711587A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Реа Колер
Ив Лобет
Стивен Рид
Original Assignee
ГлаксоСмитКлайн Байолоджикалз с.а.
Инфекшес Дизиз Рисерч Инститьют (Идри)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ГлаксоСмитКлайн Байолоджикалз с.а., Инфекшес Дизиз Рисерч Инститьют (Идри) filed Critical ГлаксоСмитКлайн Байолоджикалз с.а.
Publication of UA98605C2 publication Critical patent/UA98605C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.
UAA200711587A 2005-04-29 2006-04-27 Novel method for preventing or treating m. tuberculosis infection UA98605C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67654905P 2005-04-29 2005-04-29

Publications (1)

Publication Number Publication Date
UA98605C2 true UA98605C2 (en) 2012-06-11

Family

ID=40006338

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA200711587A UA98605C2 (en) 2005-04-29 2006-04-27 Novel method for preventing or treating m. tuberculosis infection
UAA201111598A UA107788C2 (en) 2005-04-29 2006-04-27 A fusion protein of m. tuberculosis

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA201111598A UA107788C2 (en) 2005-04-29 2006-04-27 A fusion protein of m. tuberculosis

Country Status (2)

Country Link
CN (1) CN105903008B (en)
UA (2) UA98605C2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2133100B1 (en) * 2000-06-20 2011-10-05 Corixa Corporation MTB32A Antigen of mycobacterium tuberculosis with inactivated active site and fusion proteins thereof
US20030175294A1 (en) * 2001-03-13 2003-09-18 Corixa Corporation Heterologous fusion protein constructs comprising a Leishmania antigen
US7026465B2 (en) * 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis

Also Published As

Publication number Publication date
CN105903008A (en) 2016-08-31
CN105903008B (en) 2020-01-03
UA107788C2 (en) 2015-02-25

Similar Documents

Publication Publication Date Title
PH12013502449A1 (en) Novel method for preventing or treating m tuberculosis infection
CY1110886T1 (en) COMPOSITIONS FOR COMBATING RESISTANCE TO B-LACTAMA MEDIUM-TREATED ANTIBODIES, USING B-LAKTAMASIS USES
TW200630093A (en) Dose forms
BR0110573A (en) Compound, pharmaceutical composition comprising such compound, process for the preparation of a pharmaceutical composition, use of the compound and process for the prophylactic or therapeutic treatment and preparation of the compound
CO5700796A2 (en) COMPOSITIONS CONTAINING PIPERACILIN AND TAZOBACTAM USEFUL FOR INJECTIONS
NO20071711L (en) Compositions containing piperacillin, tazobactam and an amino carboxylic acid in a sodium lactate diluent
BRPI0415953B8 (en) controlled release dosage formulation and set of controlled release dosage forms
PE20190351A1 (en) HUNTER'S SYNDROME THERAPEUTIC AGENT AND METHOD OF TREATMENT
MX2022013615A (en) Macrocyclic inhibitors of peptidylarginine deiminases.
WO2005030109A3 (en) Regimen for the administration of rifamycin-class antibiotics
ECSP044985A (en) SINGLE DOSE AZITHROMYCIN FOR RESPIRATORY INFECTIONS
UA98605C2 (en) Novel method for preventing or treating m. tuberculosis infection
EA200401303A1 (en) MEDICINES CONTAINING STEROIDS AND NEW ANTICHOLINERGIC MEANS
CY1115823T1 (en) NEW METHOD FOR PREVENTION OR TREATMENT OF INFECTION M. TUBERCULOSIS
WO2005082396A3 (en) Use of mda-7 to inhibit infection by pathogenic organisms
BR0307196A (en) Idraparinux (sanorg 34006) for treatment and secondary prophylaxis of venous thromboembolic events in patients with deep vein thrombosis.
DK1677808T3 (en) Combination preparation for the treatment of sepsis
TH1701007800A (en) Metallo-beta-lactamase inhibitor
TW200618812A (en) Compositions containing piperacillin and tazobactam useful for injection
WO2015027040A3 (en) Methods and compositions for treating schistosome infection
UA6910U (en) Method for treating acute enteric infections in children
TH77205B (en) Combination vaccine containing the bovine diarrhea virus Softened
TH91790A (en) Combination vaccine containing the bovine diarrhea virus Softened